GlaxoSmithKline PLC Financials
| GSK Stock | USD 33.70 0.35 1.05% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Profit Margin | 0.23 | 0.1625 |
|
| |||||
| Return On Assets | 0.17 | 0.0835 |
|
| |||||
| Operating Income | 4.9 B | 6.7 B |
|
| |||||
| Current Ratio | 1.51 | 0.8849 |
|
|
The financial analysis of GlaxoSmithKline PLC is a critical element in measuring its lifeblood. Investors should not minimize GlaxoSmithKline PLC's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
GlaxoSmithKline | Select Account or Indicator |
Understanding current and past GlaxoSmithKline PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GlaxoSmithKline PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in GlaxoSmithKline PLC's assets may result in an increase in income on the income statement.
GlaxoSmithKline PLC Stock Summary
GlaxoSmithKline PLC competes with Novartis, AstraZeneca PLC, Roche Holding, Bristol Myers, and Amgen. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States.| Foreign Associate | UK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | US37733W2044 |
| CUSIP | 37733W105 37733W204 |
| Location | United Kingdom |
| Business Address | 980 Great West |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gsk.com |
| Phone | 44 20 8047 5000 |
| Currency | USD - US Dollar |
GlaxoSmithKline PLC Key Financial Ratios
| Return On Equity | 0.22 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Price To Sales | 2.17 X | ||||
| Revenue | 30.33 B |
GlaxoSmithKline PLC Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
| Other Current Liab | 755M | 13.5B | 15.0B | 14.5B | 13.8B | 14.5B | |
| Net Debt | 25.8B | 20.9B | 19.9B | 17.3B | 15.1B | 8.3B | |
| Accounts Payable | 14.9B | 4.4B | 4.5B | 3.9B | 3.7B | 5.1B | |
| Cash | 4.7B | 6.3B | 4.3B | 3.7B | 2.9B | 2.7B | |
| Inventory | 5.9B | 6.0B | 5.8B | 5.1B | 5.5B | 3.0B | |
| Total Liab | 61.3B | 59.6B | 57.8B | 50.1B | 46.2B | 25.5B | |
| Total Current Assets | 19.5B | 20.2B | 18.7B | 20.8B | 18.6B | 11.9B | |
| Capital Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
| Short Term Debt | 6.9B | 3.7B | 3.6B | 4.0B | 2.8B | 2.2B | |
| Common Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
| Retained Earnings | 5.1B | 6.8B | 7.9B | 4.4B | 7.7B | 8.1B | |
| Intangible Assets | 31.0B | 29.8B | 30.1B | 14.3B | 14.8B | 11.4B | |
| Other Liab | 13.7B | 14.1B | 13.5B | 10.2B | 11.7B | 14.2B | |
| Long Term Debt | 22.6B | 23.4B | 20.6B | 17.0B | 14.2B | 17.5B | |
| Good Will | 10.6B | 10.6B | 10.6B | 7.0B | 6.8B | 5.3B | |
| Other Current Assets | 1.6B | 1.9B | 1.7B | 1.4B | 1.6B | 1.5B | |
| Other Assets | 5.1B | 5.3B | 6.9B | 6.9B | 7.9B | 5.4B | |
| Net Receivables | 7.1B | 5.5B | 6.2B | 5.5B | 5.9B | 6.1B | |
| Net Tangible Assets | (30.1B) | (25.8B) | (25.6B) | (10.8B) | (12.4B) | (13.0B) | |
| Short Long Term Debt | 6.7B | 3.5B | 3.4B | 3.8B | 2.7B | 4.3B |
GlaxoSmithKline PLC Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 912M | 892M | 784M | 879M | 775M | 502.2M | |
| Total Revenue | 33.8B | 34.1B | 34.1B | 29.3B | 30.3B | 19.9B | |
| Gross Profit | 21.9B | 22.4B | 22.5B | 19.8B | 21.3B | 14.6B | |
| Operating Income | 7.0B | 6.0B | 4.4B | 6.4B | 6.7B | 4.9B | |
| Ebit | 10.1B | 5.7B | 5.6B | 6.5B | 6.8B | 5.4B | |
| Research Development | 4.6B | 5.1B | 5.3B | 5.5B | 6.2B | 6.5B | |
| Ebitda | 10.1B | 8.1B | 7.8B | 8.6B | 9.1B | 6.4B | |
| Income Before Tax | 6.2B | 5.2B | 3.6B | 5.6B | 6.1B | 4.7B | |
| Net Income | 4.6B | 5.7B | 4.4B | 15.0B | 4.9B | 3.7B | |
| Income Tax Expense | 953M | 67M | 83M | 707M | 756M | 1.2B | |
| Cost Of Revenue | 11.9B | 11.7B | 11.6B | 9.6B | 9.1B | 7.7B | |
| Minority Interest | 7.0B | 6.2B | (711M) | (665M) | (380M) | (361M) | |
| Tax Provision | 953M | 580M | 346M | 707M | 756M | 669.3M | |
| Interest Income | 708M | 44M | 723M | 76M | 48M | 45.6M | |
| Net Interest Income | (840M) | (848M) | (756M) | (803M) | (735M) | (771.8M) |
GlaxoSmithKline PLC Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 300M | 119M | 25M | (269M) | (424M) | (402.8M) | |
| Change In Cash | 744M | 431M | (1.4B) | (394M) | (567M) | (538.7M) | |
| Free Cash Flow | 5.9B | 6.2B | 5.0B | 5.1B | 4.0B | 3.4B | |
| Depreciation | 3.0B | 624M | 2.5B | 2.3B | 2.3B | 1.4B | |
| Other Non Cash Items | 814M | 848M | 756M | (433M) | 468M | 491.4M | |
| Capital Expenditures | 2.2B | 2.2B | 2.9B | 2.3B | 2.3B | 1.5B | |
| Net Income | 5.3B | 6.4B | 5.1B | 4.9B | 4.9B | 4.6B | |
| End Period Cash Flow | 4.8B | 5.3B | 3.8B | 3.4B | 2.9B | 2.1B | |
| Dividends Paid | 4.0B | 4.0B | 4.0B | 3.5B | 2.2B | 3.4B | |
| Investments | (5.4B) | 2.2B | 334M | (8.8B) | (1.6B) | (1.5B) | |
| Net Borrowings | 3.5B | (4.2B) | (2.2B) | (4.8B) | (5.5B) | (5.8B) | |
| Change To Netincome | 670M | 380M | 105M | (8.3B) | (9.6B) | (10.1B) |
GlaxoSmithKline Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline PLC's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline PLC competition to find correlations between indicators driving GlaxoSmithKline PLC's intrinsic value. More Info.GlaxoSmithKline PLC ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.33 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for GlaxoSmithKline PLC ADR is roughly 3.02 . At this time, GlaxoSmithKline PLC's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GlaxoSmithKline PLC by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.GlaxoSmithKline PLC ADR Systematic Risk
GlaxoSmithKline PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GlaxoSmithKline PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on GlaxoSmithKline PLC ADR correlated with the market. If Beta is less than 0 GlaxoSmithKline PLC generally moves in the opposite direction as compared to the market. If GlaxoSmithKline PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GlaxoSmithKline PLC ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GlaxoSmithKline PLC is generally in the same direction as the market. If Beta > 1 GlaxoSmithKline PLC moves generally in the same direction as, but more than the movement of the benchmark.
GlaxoSmithKline PLC Thematic Clasifications
GlaxoSmithKline PLC ADR is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Healthcare | View |
Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GlaxoSmithKline PLC growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
GlaxoSmithKline PLC November 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of GlaxoSmithKline PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GlaxoSmithKline PLC ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on widely used predictive technical indicators. In general, we focus on analyzing GlaxoSmithKline Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GlaxoSmithKline PLC's daily price indicators and compare them against related drivers.
| Information Ratio | (0.26) | |||
| Maximum Drawdown | 8.87 | |||
| Value At Risk | (2.56) | |||
| Potential Upside | 1.89 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.